University of Liverpool
Latest From University of Liverpool
Blueberry Therapeutics Ltd. plans to exploit nanopolymer drug delivery technologies to create safer and more effective therapeutics to treat inflammation and infection. It will start by targeting OTC indications using nanotechnology and off-patent drugs, as this will enable its candidates to move toward the market more quickly and generate revenue.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2014.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.